Revolade™ (eltrombopag olamine)

REVOLADE offers a flexible dosing schedule that fits patients’ lifestyles¹

REVOLADE offers dosing flexibility and convenience

In addition, once-daily dosing with REVOLADE leads to long-term control,¹ without the fear of developing neutralising antibodies.^2-4

Review the long-term efficacy data in ITP

References:

1. REVOLADE Summary of Product Characteristics. February 2019. 2. Lum SH, Grainger JD. Eltrombopag for the treatment of aplastic anemia: current perspectives. Drug Des Devel Ther. 2016;10:2833-2843. 3. Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10-23. 4. Cheng G. Eltrombopag, a thrombopoietin-receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile. Ther Adv Hematol. 2012;3(3):155-164.

Disclaimer: This is an international website for REVOLADE^® (eltrombopag) and is intended for health care professionals outside the US. If you are a US resident, please click on the US Residents links at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

With REVOLADE, Patients Can Achieve Sustained Response on Their Terms1

REVOLADE offers a flexible dosing schedule that fits patients’ lifestyles1

With REVOLADE, Patients Can
Achieve Sustained Response on Their Terms¹

REVOLADE offers a flexible dosing schedule that fits patients’ lifestyles¹